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Abstract 
 
Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy 
against HER2-positive breast and gastric cancers; however, acquired resistance presents a 
formidable obstacle to long-term tumor responses in the majority of patients. Here, we show 
the mechanism of resistance to trastuzumab in HER2-positive human cancer cells and explore 
molecular sensitization by exogenous expression of HER2-extracellular domain (ECD) in 
HER2-negative or trastuzumab-resistant human cancer cells. We found that long-term 
exposure to trastuzumab induced resistance in HER2-positive cancer cells; HER2 expression 
was downregulated, and antibody-dependent cellular cytotoxicity (ADCC) activity was 
impaired. We next examined the hypothesis that trastuzumab-resistant cells could be 
re-sensitized by the transfer of non-functional HER2-ECD. Exogenous HER2-ECD 
expression induced by the stable transfection of a plasmid vector or infection with a 
replication-deficient adenovirus vector had no apparent effect on the signaling pathway, but 
strongly enhanced ADCC activity in low HER2-expressing or trastuzumab-resistant human 
cancer cells. Our data indicate that restoration of HER2-ECD expression sensitizes 
HER2-negative or HER2-downregulated human cancer cells to trastuzumab-mediated ADCC, 
an outcome that has important implications for the treatment of human cancers. 
 
Key words: HER2; extracellular domain; trastuzumab; ADCC; adenovirus. 
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Introduction 
 
Human epidermal growth factor receptor 2 (HER2) is a member of a receptor family 
associated with tumor cell proliferation, adhesion, migration, and differentiation [1]. 
Trastuzumab, a humanized monoclonal antibody that targets HER2, inhibits the 
HER2-mediated signaling pathway [2, 3] and also induces antibody-dependent cellular 
cytotoxicity (ADCC) [4-7]. The randomized clinical trial that led to the approval of 
trastuzumab for clinical use was conducted in combination with standard cytotoxic 
chemotherapy [8]. Subsequent trials have confirmed the utility of trastuzumab in 
HER2-overexpressing breast cancer in various clinical scenarios [9]. Recently, the efficacy 
and safety of adding trastuzumab to chemotherapy in HER2-positive advanced gastric cancer 
was evaluated, and the combination therapy was found to be significantly superior to 
chemotherapy alone [10]. However, HER2 is overexpressed only in approximately 20% of 
primary breast and gastric cancers [8, 11-13]. Moreover, even if the HER2 status is positive, 
the majority of patients that initially respond to trastuzumab eventually develop resistance [9, 
14, 15]. Thus, more effective treatments against HER2-overexpressing cancer require a 
deeper understanding of the mechanisms of resistance to trastuzumab.  
 Several mechanisms for trastuzumab resistance have been proposed, including the 
truncation of the HER2 receptor into a constitutively activated form (p95HER2) [16, 17], 
increased cellular signaling through alternative receptor tyrosine kinases [18-20], and altered 
intracellular signaling involving the loss of PTEN [21-23], which increases Akt activity. 
However, the biochemical nature of the resistance mechanism is confusing and controversial. 
Although the activation of ADCC is an important antitumor mechanism of trastuzumab, few 
Yoshida et al., Page 5 
studies have examined the role of ADCC in trastuzumab resistance. ADCC relies on the 
binding of antigen–antibody complexes to Fcγ receptors expressed on immune cells, and it is 
mainly attributable to the activation of natural killer (NK) cells. In fact, ADCC and overall 
NK cell activity were found to correlate with responses to trastuzumab [24]. Tumor cells 
potentially avoid ADCC attack from therapeutic antibodies by various mechanisms, such as 
insufficient recruitment of effector cells into tumors and the reduction or elimination of 
antigen expression on tumor cells [25].  
 Several strategies have been proposed to resensitize resistant tumor cells to 
therapeutic antibodies. In particular, the modification of heterogeneous or decreased antigen 
expression in resistant tumor cells might overcome resistance by enhancing ADCC activity. 
HER2 contains an extracellular ligand-binding domain, a short hydrophobic transmembrane 
region, and a cytoplasmic tyrosine kinase domain, which is crucial for downstream signaling 
[26]. Therefore, we hypothesize that truncated HER2 without an intracellular domain could 
be used as a non-signaling target for ADCC. 
 In the present study, we analyzed the HER2 surface expression and ADCC 
susceptibility of HER2-positive human cancer cells following repeated exposure to 
trastuzumab. We found that the surviving cells had reduced HER2 expression and were 
consequently less susceptible to ADCC. Moreover, we explored the effect of exogenous 
overexpression of the extracellular domain (ECD) of HER2, which lacks an intracellular 
signaling fragment, in HER2-negative and trastuzumab-resistant human cancer cells.  
 
Materials and methods 
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Cell lines and cell cultures  
 
Three human mammary gland adenocarcinoma cell lines, SKBR3, BT474, and MCF7, were 
obtained from American Type Culture Collection. SKBR3 was cultured in McCoy’s 5A 
medium. BT474 was cultured in Leibovitz’s medium. MCF7 was cultured in DMEM 
supplemented with 2 mmol/mL L-glutamine. The human gastric adenocarcinoma cell lines 
MKN1 and MKN28 were obtained from Human Science Research Resources Bank and 
cultured in RPMI1640. Penicillin (100 units/mL), streptomycin (100 μg/mL) and 10% fetal 
bovine serum were added to the medium for each cell line. 
 
Construction of plasmids and establishment of stable cell lines 
 
Complementary DNAs of human full-length HER2 (HER2-wt) and truncated HER2 
containing extracellular and transmembrane regions (HER2-ECD) were kindly provided by 
Dr. Mien-Chie Hung (M.D. Anderson Cancer Center). HER2-wt and HER2-ECD cDNAs 
were subcloned into the multi-cloning sites of the pcDNA3 vector. MCF7 breast cancer cells 
were transfected with the vectors expressing HER2-wt or HER2-ECD. For selection of stably 
transfected cells, cells were maintained in medium containing 0.2 mg/mL geneticin (G418), 
and single colonies were isolated. 
 
Recombinant adenovirus 
 
Replication-deficient adenoviral vector expressing the extracellular and transmembrane 
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domains of HER2 (Ad-HER2-ECD) was constructed. Briefly, the HER2-ECD expression 
cassette that contains the human cytomegalovirus promoter, HER2-ECD cDNA, and the 
SV40 early polyadenylation signal was inserted between the XbaI and ClaI sites of pXCJL.1. 
The HER2-ECD shuttle vector and the recombinant plasmid pJM17 were cotransfected into 
293 cells (Ad5-transformed human embryonic kidney cell line). The culture supernatant of 
293 cells showing the complete cytopathic effect was collected and used for subsequent 
infections. This virus was purified by ultracentrifugation in cesium chloride step gradients, 
and its titer was determined by a plaque-forming assay using 293 cells. Replication-deficient 
E1A-deleted adenovirus (dl312) was used as control adenovirus. The viruses were stored at 
-80°C before use.  
 
Establishment of trastuzumab-acquired auto-resistance in HER2-positive cancer cells  
 
To establish the trastuzumab-resistant cells, human breast cancer cell lines SKBR3 and 
BT474 expressing HER2 were exposed to increasing concentrations of the anti-HER2 
monoclonal antibody trastuzumab (Chugai Pharmaceutical Co.) for more than 3 months. 
Briefly, HER2-positive cancer cells were initially exposed to 50 mg/ml trastuzumab for 1 
month followed by 100 mg/ml trastuzumab for 2 months. Trastuzumab was administered 
twice a week. Trastuzumab-resistant cells established by continuous exposure to trastuzumab 
were maintained in medium with 100 mg/ml trastuzumab. The trastuzumab-resistant cancer 
cells were cultured in medium without trastuzumab for 5 days before each experiment.  
 
Western blotting analysis 
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Primary antibodies against HER2-ECD (Thermo Scientific); β-actin (Sigma Chemical, Co.); 
PTEN (Santa Cruz); and HER2-intracellular domain, IGF1-R, pAkt, pmTOR, pHER3, Akt, 
and mTOR (Cell Signaling Technology) and peroxidase-linked secondary antibodies 
(Amersham) were used. Proteins were electrophoretically transferred to 
Hybond-polyvinylidene difluoride transfer membranes (GE Healthcare Life Science) and 
incubated with primary antibody, followed by peroxidase-linked secondary antibody 
according to the manufacturer’s protocol. The Amersham ECL chemiluminescence system 
(GE Healthcare Life Science) was used to detect the peroxidase activity of the bound antibody. 
In experiments with replication-deficient adenoviral vector, cells were infected with 
Ad-HER2-ECD or dl312 at a multiplicity of infection (MOI) of 20 for 36 hours. 
 
Flow cytometric analysis 
 
In experiments to measure the affinity to trastuzumab, tumor cells were pre-treated with 100 
μg/mL of trastuzumab for 60 minutes at 37°C. Tumor cells were fixed with 4% 
paraformaldehyde in PBS for 10 minutes and then washed with PBS containing 0.5% or 1.5% 
BSA. The cells were labeled with APC-conjugated rabbit monoclonal anti-HER2-ECD 
antibody (R&D Systems Inc.) or APC-conjugated AffiniPure F(ab’)2 fragment goat 
monoclonal anti-human IgG + IgM (H+L) antibody (Jackson ImmunoResearch Laboratories, 
Inc.) at room temperature for 45 min and analyzed by FACSAria instrument (BD 
Biosciences). The cell population was gated on forward scatter and side scatter. The intensity 
of staining was determined by the BD-FACS Software. In experiments with 
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replication-deficient adenoviral vector, cells were infected with Ad-HER2-ECD at an MOI of 
20 for 36 hours. 
 
Cell viability assay 
 
Parental or trastuzumab-resistant human breast cancer cells were seeded on 96-well plates at a 
density of 1×103 cells/well for 24 h. Then, trastuzumab was added to every well at the 
indicated concentration for 5 days. Cell viability was determined 5 days after trastuzumab 
treatment by using the Cell Proliferation Kit II (Roche Molecular Biochemicals) with the 
sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene 
sulfonic acid hydrate (XTT) assay, according to the manufacturer’s protocol.  
 
Cell proliferation assays 
 
Cells were trypsinized and re-plated in 24-well plates at a density of 1×104 cells/well. 
Parental MCF7 cells, mock vector-treated MCF7 cells, MCF7-HER2-wt cells and 
MCF7-HER2-ECD cells were analyzed. Cells were incubated for 12 h to allow for attachment, 
after which the zero time point was determined. In experiments with adenoviral vector, 
trastuzumab-resistant SKBR3 or BT-47 cells with downregulated HER2 expression or low 
HER2-expressing breast and gastric cancer cells were infected with replication-deficient 
adenovirus (MOI, 20) one day after the zero time point. 
  
Antibody-dependent cellular cytotoxicity (ADCC) assay 
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Peripheral blood mononuclear cells (PBMCs) were separated from peripheral blood obtained 
from healthy donors by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient 
centrifugation. After centrifugation, PBMCs were washed three times with PBS and 
suspended with medium containing 10% FBS. Target cells were labeled with 50 μCi (1.85 
MBq) of Na51Ci (Parkin Elmer, Waltham, Mass) for 60 minutes. Then, target cells (1 × 10
4
/ 
well) and effector cells at various effector/target ratios were co-incubated in 200 μL of 
X-VIVO medium in a 96-well U-bottomed plate for 4h at 37°C with trastuzumab (2 μg/well; 
Chugai Pharmaceutical co.) or control antibody, rituximab (2 μg/well; Chugai Pharmaceutical 
Co.). After 4h of incubation, the radioactivity of the supernatant (100 μL) was measured with 
a γ-counter. The percentage of specific lysis = 100× (experimental count per minute (cpm) – 
spontaneous cpm) / (maximum cpm – spontaneous cpm). In experiments with 
replication-deficient adenovirus, target cells were infected with Ad-HER2-ECD or dl312 at 
an MOI) of 20 for 36 h (MCF7 and MDA-MB-231 cells) or 24 h (trastuzumab-resistant 
SKBR3 or BT474, MKN1, and MKN28 cells) before the ADCC assay was performed. 
 
Statistical analysis 
 
A comparison of continuous variables between two groups for in vitro assays was performed 
with the two-sided Student’s t test. At least three independent experiments were performed. 
The differences between groups were considered to be statistically significant when the P 
values were less than 0.05. Means and 95% confidence intervals are reported, unless 
otherwise indicated. All data were analyzed with the statistical software SPSS 15.0 (SPSS, 
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Inc, Chicago, IL).  
 
Results 
 
Continuous exposure to trastuzumab downregulates cell-surface HER2 expression and 
impairs trastuzumab-mediated ADCC in HER2-positive human cancer cells  
 
To elucidate the molecular mechanism of developing resistance to trastuzumab, we 
continuously treated HER2-positive SKBR3 and BT474 breast cancer cells with trastuzumab. 
Exposure to trastuzumab for one month reduced extracellular HER2 levels in both cell lines, 
and this downregulation was maintained for at least 2 months. HER2 downregulation did not 
recover following 5 days of incubation in the absence of trastuzumab (Fig. 1a). Intracellular 
HER2 expression was also reduced by long-term exposure to trastuzumab, although 
p95HER2 could not be detected (Supplemental Fig. 1). Flow cytometric analysis 
demonstrated that trastuzumab-exposed SKBR3 and BT474 cells showed decreased HER2 
expression as compared with parental lines, leading to reduced affinity to trastuzumab (Fig. 
1b).  
 SKBR3 and BT474 cells exposed to trastuzumab for 3 months were apparently more 
resistant to trastuzumab-mediated growth suppression in vitro (Fig. 1c). Western blotting 
analysis for assessment of the HER2-related signaling pathway demonstrated that 
phosphorylated Akt and mTOR expression were downregulated in these resistant cell lines. In 
contrast, insulin like growth factor-1 receptor (IGF-1R) expression was notably enhanced 
following trastuzumab exposure in SKBR3 cells and constitutively high in BT474 cells 
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without trastuzumab treatment (Fig. 1d). These results suggest that the development of 
resistance to trastuzumab at least partially depends on upregulation of an alternative signaling 
pathway downstream of other receptor tyrosine kinases such as IGF-1R. We further examined 
trastuzumab-mediated ADCC against parental and trastuzumab-resistant SKBR3 and BT474 
cells by using PBMCs from healthy volunteer donors. Although apparent ADCC activity was 
observed in parental SKBR3 and BT474 cells, long-term exposure to trastuzumab 
significantly reduced this activity in both cell lines (Fig. 1e). Thus, impaired ADCC activity 
might be another possible mechanism contributing to acquired trastuzumab resistance.  
 
Effects of exogenous HER2-ECD expression on in vitro growth and signaling pathways in 
human cancer cells  
 
To investigate the effects of exogenous expression of HER2 protein on trastuzumab-mediated 
antitumor activity, we transfected human full-length HER2 (HER2-wt) and truncated HER2 c 
DNA containing extracellular and transmembrane regions (HER2-ECD) into low 
HER2-expressing MCF7 human breast cancer cells. HER2 overexpression contributes to 
breast cancer carcinogenesis, and studies have indicated that transfection of HER2-wt into 
mammary epithelial cells induces oncogenic transformation [27]. Indeed, stable 
HER2-wt-expressing MCF7 cells showed accelerated cell growth compared to parental 
MCF7 cells, whereas the growth pattern of HER2-ECD-transfected MCF7 cells was similar 
to that of parental MCF7 cells (Fig. 2a). Furthermore, transfection of HER2-wt, but not 
HER2-ECD, led to an increase in phosphorylated Akt and mTOR expression in the presence 
of HER3 ligand, HRG-; these results suggest that exogenous HER2-ECD expression did not 
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trigger the signaling pathways of HER2/HER3, which is the most potent combination of 
receptors in human breast cancer cells [28, 29] (Fig. 2b). 
 We next explored whether exogenous expression of HER2-wt or HER2-ECD was 
altered by long-term exposure to trastuzumab. The expression of 185-kDa full-length HER2 
protein was slightly reduced in the presence of trastuzumab, whereas 3-month treatment with 
trastuzumab resulted in a slight increase in 100-kDa HER2-ECD expression (Fig. 2c). 
However, flow cytometric analysis demonstrated that neither cell-surface HER2 expression 
nor trastuzumab binding affinity changed following long-term trastuzumab exposure (Fig. 2d). 
Furthermore, the ADCC activity of trastuzumab against MCF7 cells transfected with 
HER2-wt or HER2-ECD was maintained even after a 3-month exposure to trastuzumab (Fig. 
2e). These results indicate that exogenous overexpression of HER2-wt or HER2-ECD could 
overcome trastuzumab-mediated downregulation of endogenous HER2 expression.  
 
Exogenous HER2-ECD expression enhances trastuzumab-mediated ADCC activity in low 
HER-2-expressing human cancer cells 
 
We conducted a standard 4-h 
51
Cr release assay with PBMCs from healthy volunteer donors 
to test the hypothesis that trastuzumab-mediated ADCC activity could be enhanced by 
exogenous overexpression of HER-ECD. With 5, 10, or 20 μg/mL of trastuzumab, ADCC 
activity was significantly increased in both HER2-ECD- and HER2-wt-expressing MCF7 
cells as compared to MCF7 cells transfected with control pcDNA3 vector. A low 
concentration of trastuzumab (1 μg/mL) failed to enhance ADCC (Fig. 3a). Furthermore, 
effector cells showed significantly increased ADCC against HER2-ECD- or 
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HER2-wt-expressing MCF7 cells as compared to pcDNA3-transfected cells at the 
effector/target cell ratios of 5:1, 10:1, 20:1, and 40:1 (Fig. 3b). These results indicate that 
exogenous overexpression of HER2-ECD may be an appropriate strategy to sensitize human 
cancer cells with low or reduced expression of HER2 to trastuzumab. Thus, we next 
examined the most efficient tool for gene transfer. 
 
Efficient HER2-ECD overexpression in human cancer cell lines by a recombinant 
replication-deficient adenovirus vector 
 
Modified adenovirus 5 (Ad5) vectors have been used as a platform to deliver genes of interest 
into various types of human cells. We constructed a replication-deficient adenoviral vector 
containing a gene that encodes the extracellular domain of HER2 plus the transmembrane 
domain (Ad-HER2-ECD). To assess the efficient exogenous HER2-ECD overexpression by 
Ad-HER2-ECD infection, we used trastuzumab-resistant and low HER2-expressing human 
breast and gastric cancer cell lines. Various HER2 tests have demonstrated that the levels of 
HER2 expression in both MKN1 and MKN28 cells are low and that MKN7 cells overexpress 
HER2 antigen (Table 1). Indeed, the degree of HER2 expression correlated well with 
trastuzumab-mediated ADCC activity (Supplemental Fig. 2).  
 As expected, Ad-HER2-ECD infection at an MOI of 20 for 36 hours resulted in a 
marked increase in the expression of 100-kDa HER2-ECD protein in trastuzumab-resistant 
breast cancer cells (SKBR3 and BT474), low HER2-expressing breast cancer cells (MCF7 
and MDA-MB-231), and low HER2-expressing gastric cancer cells (MKN1 and MKN28) as 
compared to mock- or control dl312-infected cells (Fig. 4a). Western blot analysis also 
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demonstrated that Ad-HER2-ECD had no apparent effects on the HER2 signaling pathway 
such as Akt and mTOR expression as well as phosphorylated mTOR expression, although 
Ad-HER2-ECD and control dl312 induced phosphorylated Akt. Flow cytometric analysis 
confirmed the cell-surface expression of HER2-ECD in Ad-HER2-ECD-infected cells, which 
in turn leads to increased trastuzumab binding (Fig. 4b).  
 
Direct antitumor effects of Ad-HER2-ECD on trastuzumab-resistant or low 
HER2-expresssing human cancer cells 
 
Next, we assessed the cell growth pattern of trastuzumab-resistant SKBR3 and BT474 human 
breast cancer cells and low HER2-expressing MKN1 and MKN28 human gastric cancer cells 
following Ad-HER2-ECD infection. MCF7 cells that were stably transfected with the 
HER2-ECD plasmid showed a growth pattern similar to that of parental or control 
vector-transfected MCF7 cells (Fig. 2a). However, adenovirus-mediated overexpression of 
HER2-ECD unexpectedly induced a significant suppression of in vitro growth in all cell lines 
as compared to uninfected cells or cells infected with control dl312 (Fig. 5). These results 
suggest that Ad-HER2-ECD had a slight but significant direct antitumor effect on 
trastuzumab-resistant and low HER2-expressing human cancer cell lines in vitro.   
 
Adenovirus-mediated HER2-ECD overexpression sensitizes trastuzumab-resistant or low 
HER2-expressing human cancer cells to trastuzumab-mediated ADCC 
 
Finally, we examined whether Ad-HER2-ECD infection could overcome acquired resistance 
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to trastuzumab-mediated ADCC in SKBR3 and BT474 human breast cancer cells. 
Enhancement of ADCC activity by Ad-HER2-ECD infection was also assessed in low 
HER2-expressing human breast and gastric cancer cell lines. Following Ad-HER2-ECD 
infection, trastuzumab-resistant (Fig. 6a) as well as low HER2-expressing cells (Fig. 6b, c) 
were more efficiently killed by ADCC, and a significant difference was detected at all 
effector/target ratios in all cell lines, except trastuzumab-resistant SKBR3 cells, as compared 
to mock- or control dl312-infected cells. Thus, Ad-HER2-ECD-mediated exogenous 
expression of HER2-ECD could sensitize trastuzumab-resistant HER2-downregulated cells or 
low HER2-expressing cells to trastuzumab through ADCC activation in vitro. 
 
Discussion 
 
The nature of acquired resistance to trastuzumab is an area of active research in both the 
laboratory and the clinic. In the present study, we exposed HER2-positive breast cancer cells 
to trastuzumab continuously in vitro to induce resistance against this antibody and investigate 
the mechanisms responsible for this resistance. Some studies indicated that trastuzumab 
treatment does not alter the cell-surface HER2 expression status [30, 31]. However, we have 
demonstrated that continuous exposure to trastuzumab results in HER2 downregulation in 
HER2-overexpressing breast cancer cell lines in vitro. Previous studies also showed that 
alternative receptor tyrosine kinase signaling may play a role in trastuzumab resistance 
[18-20]. In fact, trastuzumab-exposed SKBR3 cells exhibited upregulated IGF-1R expression, 
suggesting that an alternative signaling pathway was enhanced to protect cells from 
trastuzumab-mediated HER2 signaling inhibition.  
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 We also found that trastuzumab-exposed HER2-overexpressing breast cancer cells 
developed impaired trastuzumab-mediated ADCC activity in vitro. The ability of trastuzumab 
to mediate ADCC activity is strictly related to HER2 density [7]. In addition, Mimura et al. 
previously reported that the HER2 status determined by flow cytometry is well correlated 
with trastuzumab-mediated ADCC activity in esophageal squamous cell carcinoma cell lines 
in vitro [32]. Taking into account these reports, we conclude that the impaired 
trastuzumab-mediated ADCC activity in trastuzumab-exposed HER2-positive human cancer 
cells was due to the downregulation of HER2 expression on the cell surface. These results led 
us to examine whether exogenous expression of the HER2 receptor on the cell surface could 
re-sensitize HER2-downregulated human cancer cells to trastuzumab via ADCC 
re-activation.  
 HER2 overexpression is a significant prognostic factor in terms of nodal status, 
tumor grade, overall survival and probability of relapse in breast cancer patients [33, 34]. 
Although reports are conflicting, some studies have suggested that HER2-positive status in 
gastric cancer is associated with poor outcomes and aggressive disease [12, 13]. As expected, 
human cancer cells transfected with the full-length functional HER2 showed accelerated cell 
growth as compared to parental cells, whereas the cell growth pattern of 
HER2-ECD-transfected low HER2-expressing human cancer cells was similar to that of 
parental cells. Furthermore, we showed that HER2-ECD transfection of low 
HER2-expressing human cancer cells did not enhance the HER2/HER3 signaling pathway, 
which is the major oncogenic signal in HER2-overexpressing breast tumors [35, 36]. 
Although transfection of HER2-ECD-expressing plasmid did not influence cell growth, 
adenovirus-mediated exogenous HER2-ECD expression significantly suppressed the tumor 
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cell growth in vitro, suggesting that the growth inhibition associated with HER2-ECD 
overexpression might be due to its levels on the cell surface. Therefore, Ad-HER2-ECD 
infection showed slightly enhanced cytotoxic activity against some types of human cancer 
cells even with the control antibody rituximab in the 
51
Cr release assay. The mechanism of 
Ad-HER2-ECD-mediated cell growth inhibition is unclear; however, it is likely to be caused 
by the restriction of other HER family receptors through the formation of heterodimers with 
exogenously expressed HER2-ECD that lacks the downstream signaling pathway.  
 Some previous studies demonstrated that primary or acquired resistance to 
trastuzumab often results from preventing the binding of antibody to the HER2 protein by 
proteins such as membrane-associated glycoprotein mucin-4 [37, 38]. In our study, even after 
a long-term exposure to trastuzumab, trastuzumab-mediated ADCC activity on stably 
HER2-ECD-expressing MCF7 cells was significantly enhanced compared to mock-treated 
MCF7 cells, and, furthermore, HER2-downregulated or low HER2-expressing human cancer 
cells could be re-sensitized to trastuzumab via re-activation of trastuzumab-mediated ADCC. 
These results indicate that the degree of antibody-mediated ADCC activity is likely to be 
correlated with the cell-surface expression levels of HER2. These results suggest that the 
HER2-downregulated or low HER2-expressing human cancer cells exogenously 
overexpressing HER2-ECD is hard to develop resistance to trastuzumab in terms of the 
importance of ADCC activity in anti-tumor effects of this antibody. 
 A previous study has demonstrated that heterogeneity and incomplete membranous 
immunoreactivity for HER2 was more common in gastric cancer than in breast cancer [39], 
suggesting that the gastric tumors diagnosed as HER2-positive by immunohistochemistry or 
fluorescent in situ hybridization are more likely to be residual and re-grow under trastuzumab 
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treatment. Therefore, molecular sensitization to trastuzumab through the expression of 
HER2-ECD is thought to be effective even against HER2-positive gastric cancer. We would 
like to examine whether the ADCC activation by exogenous HER2-ECD expression 
functions in vivo; however, since murine NK cells do not recognize trastuzumab which is a 
humanized antibody, the in vivo experiments are hard to be performed. The genetically 
engineered fluorescent tumor cells as well as the whole-body fluorescent imaging technology 
may be available for such kinds of in vivo studies [40, 41].  
 Although the strategy for molecular sensitization to trastuzumab via ADCC 
activation by using an adenoviral vector is considered to be effective, some limitations exist; 
for example, there are variations in the efficiency of viral infection and the expression levels 
of exogenous HER2-ECD. As we used a replication-deficient adenovirus vector, the viral 
spread might be less than ideal after intratumoral administration. We previously developed a 
telomerase-specific oncolytic adenovirus that causes cell death in human cancer cells with 
telomerase activities. These oncolytic viruses engineered to replicate in tumor cells but not in 
normal cells could be used as tumor-specific vectors carrying therapeutic genes such as 
HER2-ECD. Moreover, ADCC activity of PBMCs from cancer patients is likely to be 
impaired due to immunosuppression and NK cell dysfunction, as previously reported for 
gastric cancer patients [42, 43]. The immunosuppressive state is associated with 
immunosuppressive cytokines such as IL-10 and TGF-. These cytokines are produced within 
the tumor microenvironment and suppress the activity of NK cells, monocytes, and T cells 
[43-46]. Therefore, to sufficiently enhance the effect of trastuzumab-mediated ADCC activity 
in cancer patients, supportive immunotherapy such as the administration of 
immune-stimulating cytokines may be required. 
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 In conclusion, our data demonstrate that HER2 downregulation and impaired ADCC 
activity may be one mechanism of trastuzumab resistance. We also show that exogenous 
overexpression of non-signaling HER2-ECD could sensitize HER2-downregulated or 
HER2-negative human cancer cells via ADCC activation, an outcome that has important 
implications for the treatment of human cancers. 
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Figure legends 
 
Figure 1 Effects of continuous exposure to trastuzumab in HER2-overexpressing breast 
cancer cells. a Western blot analysis of HER2 expression. Human breast cancer SKBR3 and 
BT474 cells were initially incubated with 50 mg/ml trastuzumab (Tzb) for 1 month followed 
by 100 mg/ml trastuzumab for 2 months. *Cells were cultured in the absence of trastuzumab 
for 5 days before analysis. Equivalent amounts of protein from whole cell lysates were loaded 
into each lane. Blots were probed with anti-HER2-ECD antibody and visualized by using an 
ECL detection system. Equal loading of samples was confirmed by stripping each blot and 
reprobing with anti-β-actin. b Flow cytometric analysis of HER2 expression and trastuzumab 
binding. Parental or trastuzumab-exposed cells were stained with APC-conjugated 
anti-HER2-ECD to measure cell-surface HER2 expression or treated with trastuzumab 
followed by incubation with APC-conjugated anti-human antibody to measure the amount of 
bound trastuzumab. c Parental or trastuzumab-exposed cells were further treated with the 
indicated doses of trastuzumab for 5 days, and cell viability was assessed by XTT assay. d 
Western blot analysis for assessment of HER2-related signaling pathway. Blots were probed 
with anti-IGF1-R, anti-PTEN, anti-phosphorylated Akt, or anti-phosphorylated mTOR. e 
ADCC activity of trastuzumab-exposed SKBR3 or BT474 cells. Parental or 
trastuzumab-exposed cells were incubated with PBMCs from healthy donors in the presence 
of 10 g/ml of trastuzumab, and the cytotoxic activity was assessed by a 4-h standard 
51
Cr-release assay. Data represent the mean ± SD of 3 wells at four different effector-to-target 
(E:T) ratios. *p < 0.05.  
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Figure 2 Effects of exogenous HER2-ECD expression in low HER2-expressing MCF7 
cells. a MCF7 human breast cancer cells were transfected with a vector expressing human 
full-length HER2 (HER2-wt) or truncated HER2 containing extracellular and transmembrane 
regions (HER2-ECD), or empty vector (mock). The cell growth was assessed for parental 
cells and stable clones. *p < 0.05. b Western blot analysis of phosphorylated HER3, Akt, and 
mTOR. Cells were stimulated with HER3 ligand, heregulin-. c Western blot analysis of 
MCF7 cells expressing HER2-wt (185kDa) or HER2-ECD (100kDa) after continuous 
exposure to trastuzumab for 1 month or 3 months. Cells were prepared as described in the 
legend for Fig. 1a. d Flow cytometric analysis of HER2 expression and the amount of bound 
trastuzumab on parental or trastuzumab-exposed MCF7 cells expressing HER2-wt or 
HER2-ECD. Cells were stained and subjected to the analysis as described in the legend to Fig. 
1B. e ADCC activity of parental or trastuzumab-exposed MCF7 cells expressing HER2-wt or 
HER2-ECD. The cytotoxic activity of PBMCs was assessed in the presence of 10 g/ml of 
trastuzumab by a 4-h standard 
51
Cr-release assay. Data represent the mean ± SD of 3 wells at 
four different E:T ratios.  
 
Figure 3 Trastuzumab-mediated ADCC activity on HER2-ECD-expressing MCF7 cells. 
a The cytotoxic activity against MCF7 human breast cancer cells transfected with vector 
expressing HER2-wt or HER2-ECD or empty vector (mock) was assessed by a 4-h standard 
51
Cr-release assay in the presence of the indicated doses of trastuzumab or control rituximab. 
Data represent the mean ± SD of 3 wells at an E:T ratio of 12.5:1. *p < 0.05. b A 4-h 
51
Cr-release assay was also performed against MCF7 cells expressing HER2-wt or 
HER2-ECD, or mock-treated MCF7 cells in the presence of 10 g/ml of trastuzumab or 
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control rituximab. Data represent the mean ± SD of 3 wells at four different E:T ratios. *p < 
0.05. 
 
Figure 4 Efficient HER2-ECD overexpression in human cancer cell lines by a 
recombinant replication-deficient adenovirus vector. a Western blot analysis of HER2-wt 
(185kDa), HER2-ECD (100kDa), and representative HER2-related signaling proteins in 
various types of human cancer cells. Trastuzumab-resistant breast cancer cells (SKBR3 and 
BT474), low HER2-expressing breast cancer cells (MCF7 and MDA-MB-231), and low 
HER2-expressing gastric cancer cells (MKN1 and MKN28) were infected with 
replication-deficient adenoviral vector expressing exogenous HER2-ECD (Ad-HER2-ECD) 
or replication-deficient control adenovirus (dl312) at an MOI of 20 for 36 hours. b Flow 
cytometric analysis of HER2 expression and the amount of bound trastuzumab in cells 36 
hours after Ad-HER2-ECD infection at an MOI of 20.  
 
Figure 5 Antitumor effects of Ad-HER2-ECD on trastuzumab-resistant or low 
HER2-expresssing human cancer cells. Trastuzumab-resistant SKBR3 and BT474 breast 
cancer cells (a) and low HER2-expressing MKN1 and MKN28 gastric cancer cells (b) 
cultured as a monolayer were infected with Ad-HER2-ECD or control dl312 at an MOI of 20. 
The cell growth was determined by counting cell numbers each day after infection. The mean 
± SD of three different wells is shown. *p < 0.05. 
 
Figure 6 Molecular sensitization of human cancer cells to trastuzumab by 
Ad-HER2-ECD-mediated exogenous expression of HER2-ECD. The cytotoxic reactivity of 
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PBMCs against HER2-downregulated SKBR3 or BT474 cells (a), low HER2-expressing 
MCF7 or MDA-MB-231 human breast cancer cells (b), or low HER2-expressing MKN1 or 
MKN28 human gastric cancer cells (c) was assessed after Ad-HER2-ECD or dl312 infection 
in the presence of 10 g/ml of trastuzumab or control rituximab by a 4-h 51Cr-release assay. 
Data represent the mean ± SD of 3 wells at four different E:T ratios. 
 








